Serum anti-myeloperoxidase antineutrophil cytoplasmic antibodies (MPO-ANCA) in patients with Graves' disease receiving anti-thyroid medication.

eruption, liver dysfunction and agranulocytosis. Furthermore manystudies have reported the development of anti-myeloperoxidase antineutrophil cytoplasmic antibody (MPOANCA)-related vasculitis and glomerulonephritis, etc, in patients treated with PTU. In the journal of Internal Medicine, Nakamoriet al also reported a case of PTU-inducedvasculitis causing pulmonary hemorrhage, anemia and microhematuria, which improved with cessation of PTUand administration of corticosteroid (1).

[1]  K. Shinohara,et al.  Propylthiouracil (PTU)-induced vasculitis associated with antineutrophil antibody against myeloperoxidase (MPO-ANCA). , 2003, Internal medicine.

[2]  K. Khiari,et al.  Une vascularite associant une atteinte rénale et pulmonaire au cours d’une maladie de Basedow traitée par le benzylthiouracile , 2002 .

[3]  K. Khiari,et al.  [Vasculitis with renal and pulmonary involvement in a patient receiving benzylthiouracil for Graves disease]. , 2002, La Revue de medecine interne.

[4]  N. Yoshioka,et al.  Prevalence of serum anti-myeloperoxidase antineutrophil cytoplasmic antibodies (MPO-ANCA) in patients with Graves' disease treated with propylthiouracil and thiamazole. , 2002, Endocrine journal.

[5]  A. Chuansumrit,et al.  Antineutrophilic cytoplasmic antibody-positive systemic vasculitis associated with propylthiouracil therapy: report of 2 children with Graves' disease. , 2002, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

[6]  M. Hattori,et al.  Clinical features and outcomes in children with antineutrophil cytoplasmic autoantibody-positive glomerulonephritis associated with propylthiouracil treatment. , 2002, Journal of the American Society of Nephrology : JASN.

[7]  K. Moriyama,et al.  Drug‐induced neutropenia associated with anti‐neutrophil cytoplasmic antibodies (ANCA): possible involvement of complement in granulocyte cytotoxicity , 2002, Clinical and experimental immunology.

[8]  N. Ishikawa,et al.  Frequency of appearance of myeloperoxidase‐antineutrophil cytoplasmic antibody (MPO‐ANCA) in Graves' disease patients treated with propylthiouracil and the relationship between MPO‐ANCA and clinical manifestations , 2001, Clinical endocrinology.

[9]  C. Kallenberg,et al.  Absence of Cross-Reactivity to Myeloperoxidase of Anti-Thyroid Microsomal Antibodies in Patients with Autoimmune Thyroid Diseases , 2001, The American journal of the medical sciences.

[10]  M. Hattori,et al.  High prevalence of antineutrophil cytoplasmic antibody positivity in childhood onset Graves' disease treated with propylthiouracil. , 2000, The Journal of clinical endocrinology and metabolism.

[11]  N. Sera,et al.  Treatment with propylthiouracil is associated with appearance of antineutrophil cytoplasmic antibodies in some patients with Graves' disease. , 2000, Thyroid : official journal of the American Thyroid Association.

[12]  J. Levine,et al.  Antineutrophil Cytoplasmic Autoantibodies Interact with Primary Granule Constituents on the Surface of Apoptotic Neutrophils in the Absence of Neutrophil Priming , 1996, The Journal of experimental medicine.

[13]  Y. Arimura,et al.  Serum myeloperoxidase and serum cytokines in anti-myeloperoxidase antibody-associated glomerulonephritis. , 1993, Clinical nephrology.

[14]  H. Hyöty,et al.  Cross-reactivity between antibodies to thyroid microsomal antigens and myeloperoxidase , 1991, The Lancet.

[15]  R. Falk,et al.  Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. , 1988, The New England journal of medicine.